Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients.
SSTR-PET/CT
everolimus
neuroendocrine tumors
response
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
12 Jun 2024
12 Jun 2024
Historique:
received:
12
03
2024
accepted:
10
05
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
11
6
2024
Statut:
aheadofprint
Résumé
This study aimed to assess This retrospective analysis included 29 patients with 62 target lesions undergoing everolimus treatment and pre-therapy, and follow-up PET/CT scans were acquired 19 days (interquartile range [IQR] 69 days) pre-treatment and 127 days (IQR 74 days) post-starting everolimus. The overall median PFS was 264 days (95% CI: 134-394 days). R exhibited significant decreases in Tmax/Lmax and Tmean/Lmax ratios compared to NR (p = 0.01). In univariate Cox regression, Tmean/Lmax ratio was the sole prognostic parameter associated with PFS (HR 0.5, 95% CI 0.28-0.92, p = 0.03). Percentage changes in T/L and T/S ratios were significant predictors of PFS, with the highest area under curve (AUC) for the percentage change of Tmean/Lmax (AUC = 0.73). An optimal threshold of < 2.5% identified patients with longer PFS (p = 0.003). No other imaging or clinical parameters were predictive of PFS. This study highlights the potential of quantitative SSTR-PET/CT in predicting and monitoring everolimus response in NET patients. Liver metastasis-to-liver parenchyma ratios outperformed size-based criteria, and Tmean/Lmax ratio may serve as a prognostic marker for PFS, warranting larger cohort investigation.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to assess
PATIENTS AND METHODS
METHODS
This retrospective analysis included 29 patients with 62 target lesions undergoing everolimus treatment and pre-therapy, and follow-up
RESULTS
RESULTS
PET/CT scans were acquired 19 days (interquartile range [IQR] 69 days) pre-treatment and 127 days (IQR 74 days) post-starting everolimus. The overall median PFS was 264 days (95% CI: 134-394 days). R exhibited significant decreases in Tmax/Lmax and Tmean/Lmax ratios compared to NR (p = 0.01). In univariate Cox regression, Tmean/Lmax ratio was the sole prognostic parameter associated with PFS (HR 0.5, 95% CI 0.28-0.92, p = 0.03). Percentage changes in T/L and T/S ratios were significant predictors of PFS, with the highest area under curve (AUC) for the percentage change of Tmean/Lmax (AUC = 0.73). An optimal threshold of < 2.5% identified patients with longer PFS (p = 0.003). No other imaging or clinical parameters were predictive of PFS.
CONCLUSIONS
CONCLUSIONS
This study highlights the potential of quantitative SSTR-PET/CT in predicting and monitoring everolimus response in NET patients. Liver metastasis-to-liver parenchyma ratios outperformed size-based criteria, and Tmean/Lmax ratio may serve as a prognostic marker for PFS, warranting larger cohort investigation.
Identifiants
pubmed: 38861687
pii: raon-2024-0032
doi: 10.2478/raon-2024-0032
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Homeira Karim et al., published by Sciendo.
Références
Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol 2018; 6: 404–15. doi: 10.1016/s2213-8587(17)30401-1
doi: 10.1016/s2213-8587(17)30401-1
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3: 1335–42. doi: 10.1001/jamaoncol.2017.0589
doi: 10.1001/jamaoncol.2017.0589
Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004; 1014: 13–27. doi: 10.1196/annals.1294.002
doi: 10.1196/annals.1294.002
Briest F, Grabowski P. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics 2014; 4: 336–65. doi: 10.7150/thno.7851
doi: 10.7150/thno.7851
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514–23. doi: 10.1056/NEJMoa1009290
doi: 10.1056/NEJMoa1009290
Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018; 19: 909–28. doi: 10.1080/14656566.2018.1476492
doi: 10.1080/14656566.2018.1476492
Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S. Treatment options for pancreatic neuroendocrine tumors. Cancers 2019; 11: 828. doi: 10.3390/cancers11060828
doi: 10.3390/cancers11060828
Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, et al. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015; 34: 823–42. doi: 10.1007/s10555-015-9598-5
doi: 10.1007/s10555-015-9598-5
Choi JI, Imagawa DK, Bhosale P, Bhargava P, Tirkes T, Seery TE, et al. Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib. Clin Mol Hepatol 2014; 20: 218–22. doi: 10.3350/cmh.2014.20.2.218
doi: 10.3350/cmh.2014.20.2.218
Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 2014; 120: 711–21. doi: 10.1002/cncr.28493
doi: 10.1002/cncr.28493
Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, Garcia-Carbonero R, Custodio A, Benavent M, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br J Cancer 2019; 121: 537–44. doi: 10.1038/s41416-019-0558-7
doi: 10.1038/s41416-019-0558-7
Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, Neumann R, Haug AR, Jansen N, et al. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging 2013; 40: 897–907. doi: 10.1007/s00259-013-2371-5
doi: 10.1007/s00259-013-2371-5
Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440: 461–75. doi: 10.1007/s00428-002-0609-x
doi: 10.1007/s00428-002-0609-x
Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010; 35: 321–8. doi: 10.1097/RLU.0b013e3181d6677c
doi: 10.1097/RLU.0b013e3181d6677c
Singh S, Poon R, Wong R, Metser U. 68Ga PET Imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis. Clin Nucl Med 2018; 43: 802–10. doi: 10.1097/rlu.0000000000002276
doi: 10.1097/rlu.0000000000002276
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 844–60. doi: 10.1016/j.annonc.2020.03.304
doi: 10.1016/j.annonc.2020.03.304
Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 2017; 29: 11–6. doi: 10.1016/j.anndiagpath.2017.04.005
doi: 10.1016/j.anndiagpath.2017.04.005
Yao JC, Pavel M, Lombard-Bohas C, Cutsem EV, Voi M, Brandt U, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 study. J Clin Oncol 2016; 34: 3906–13. doi: 10.1200/jco.2016.68.0702
doi: 10.1200/jco.2016.68.0702
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968–77. doi: 10.1016/s0140-6736(15)00817-x
doi: 10.1016/s0140-6736(15)00817-x
Cherk MH, Kong G, Hicks RJ, Hofman MS. Changes in biodistribution on (68)Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cancer Imaging 2018; 18: 3. doi: 10.1186/s40644-018-0136-x
doi: 10.1186/s40644-018-0136-x
Weber M, Telli T, Kersting D, Seifert R. Prognostic implications of PET-derived tumor volume and uptake in patients with neuroendocrine tumors. Cancers 2023; 15: 3581. doi: 10.3390/cancers15143581
doi: 10.3390/cancers15143581
Kratochwil C, Mavriopoulou E, Rath D, Afshar-Oromieh A, Apostolopoulos D, Haufe S, et al. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy. Q J Nucl Med Mol Imaging 2015; 59: 116–20. PMID: 24382404
pubmed: 24382404
Sarikaya I, Sarikaya A, Alnafisi N, Alenezi S. Significance of splenic uptake on somatostatin receptor imaging studies. Nucl Med Rev Cent East Eur 2018; 21: 66–70. doi: 10.5603/NMR.a2018.0012
doi: 10.5603/NMR.a2018.0012
Schieren G, Bölke E, Scherer A, Raffel A, Gerber PA, Kröpil P, et al. Severe everolimus-induced steatohepatis: a case report. Eur J Med Res 2013; 18: 22. doi: 10.1186/2047-783x-18-22
doi: 10.1186/2047-783x-18-22
Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem 2001; 44: 2027–34. doi: 10.1021/jm010079y
doi: 10.1021/jm010079y
Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? Diagn Interven Imaging 2014; 95: 289–300. doi: 10.1016/j.diii.2013.07.006
doi: 10.1016/j.diii.2013.07.006
Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of prrt in neuroendocrine tumors. Mol Imag Biol: 2015; 17: 313–8. doi: 10.1007/s11307-014-0795-3
doi: 10.1007/s11307-014-0795-3
Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. (68) Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol 2019; 141: 108–115. doi: 10.1016/j.radonc.2019.09.003
doi: 10.1016/j.radonc.2019.09.003
Kim YI, Yoo C, Oh SJ, Lee SJ, Kang J, Hwang HS, et al. Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res 2020; 10: 63. doi: 10.1186/s13550-020-00651-z
doi: 10.1186/s13550-020-00651-z
Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, et al. Early changes of the standardized uptake values (SUV(max)) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer. Cancers 2020; 12: 3314 doi: 10.3390/cancers12113314
doi: 10.3390/cancers12113314
Michl M, Lehner S, Paprottka PM, Ilhan H, Bartenstein P, Heinemann V, et al. Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer. J Nucl Med 2016; 57: 355–60. doi: 10.2967/jnumed.115.165613
doi: 10.2967/jnumed.115.165613
Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010; 51: 1349–56. doi: 10.2967/jnumed.110.075002
doi: 10.2967/jnumed.110.075002
Opalińska M, Morawiec-Sławek K, Kania-Kuc A, Al Maraih I, Sowa-Staszczak A, Hubalewska-Dydejczyk A. Potential value of pre- and post-therapy [68Ga] Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors. Front Endocrinol 2022; 13: 929391. doi: 10.3389/fendo.2022.929391
doi: 10.3389/fendo.2022.929391
Ingenerf M, Kiesl S, Karim S, Beyer L, Ilhan H, Rübenthaler J, et al. (68) Ga-DOTATATE PET/CT and MRI with diffusion-weighted imaging (DWI) in short- and long-term assessment of tumor response of neuroendocrine liver metastases (NELM) following transarterial radioembolization (TARE). Cancers 2021; 13: 4321. doi: 10.3390/cancers13174321
doi: 10.3390/cancers13174321
O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 2016; 280: 576–84. doi: 10.1148/radiol.2016142043
doi: 10.1148/radiol.2016142043
Ilan E, Velikyan I, Sandström M, Sundin A, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATE. J Nucl Med 2020; 61: 217–21. doi: 10.2967/jnumed.119.228072
doi: 10.2967/jnumed.119.228072